Insiderkäufe bei XOMA !


Seite 1 von 2
Neuester Beitrag: 11.11.09 19:47
Eröffnet am:22.05.09 12:06von: 10MioEuroAnzahl Beiträge:48
Neuester Beitrag:11.11.09 19:47von: andyyLeser gesamt:12.682
Forum:Börse Leser heute:1
Bewertet mit:
10


 
Seite: <
| 2 >  

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroInsiderkäufe bei XOMA !

 
  
    #1
10
22.05.09 12:06

5662 Postings, 6062 Tage _bbb_hm...

 
  
    #2
1
22.05.09 12:14
Wedbush Morgan Securities - XOMA "buy"
09:51 15.05.09

Rating-Update:

Los Angeles (aktiencheck.de AG) - Die Analystin Liana Moussatos von Wedbush Morgan Securities stuft die Aktie von XOMA (Profil) weiterhin mit dem Rating "buy" ein. Das Kursziel werde unverändert bei 2 USD gesehen. (15.05.2009/ac/a/u)  

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroDie Meldung über Insidertransaktionen

 
  
    #3
4
22.05.09 12:23
kam gestern nachbörslich.
Der Kurs hat noch gar nicht reagieren können.

5662 Postings, 6062 Tage _bbb_Monatschart

 
  
    #4
22.05.09 12:32

 

5662 Postings, 6062 Tage _bbb_Wochenchart

 
  
    #5
22.05.09 12:33

 

5662 Postings, 6062 Tage _bbb_Wochenchart

 
  
    #6
22.05.09 12:34

 

5662 Postings, 6062 Tage _bbb_Pipeline

 
  
    #7
22.05.09 12:55

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroHier die wichtigste Meldung überhaupt!

 
  
    #9
2
22.05.09 13:56

diese hat auch die Kursexplosion vor 8-Tagen eingeleitet (man beachte auch die Umsätze) , die Konsolidierung scheint abgeschlossen zu sein. Jetzt wieder die Chance bei der nächsten Kaufwelle dabei zu sein (ausgelöst durch die Insiderkäufe).

app.quotemedia.com/quotetools/newsStoryPopup.go

 und hier mehr zum Thema:

www.presseportal.de/pm/62265/1405654/ucb_gmbh

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroweiterer Insiderkauf: Filing vom 22.05.

 
  
    #10
3
23.05.09 16:29

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroFiling vom 22.05: SC 13G (Insider Transactions)

 
  
    #11
3
23.05.09 16:33

5662 Postings, 6062 Tage _bbb_XOMA News

 
  
    #12
1
26.05.09 19:42
Press Release Source: XOMA Ltd.
XOMA Announces Clinical and Preclinical Presentations At American Diabetes Association 69th Scientific Sessions
On Tuesday May 26, 2009

http://finance.yahoo.com/news/...ounces-Clinical-and-pz-15346685.html  

53 Postings, 5515 Tage appolon4ikwir haben einen bullenmarkt,

 
  
    #14
27.05.09 01:06

1398 Postings, 6307 Tage CosmicTradeXOMA...das Volk hat sich ausgekotzt....

 
  
    #15
27.05.09 10:10

 

Nasdaq Day-Chart USA

 

Xoma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroTue, May 26, 2009 2:33 PM,

 
  
    #16
2
27.05.09 11:42

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroCT ORDER (Filed: 27-05-2009)

 
  
    #17
2
27.05.09 19:41

1398 Postings, 6307 Tage CosmicTradeXOMA...good news...

 
  
    #18
28.05.09 08:34
After Hour Quotes USA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kraig Biocraft Laboratories, Inc. Gears Up to Double the Number of Genetic Insertions Performed and Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452.
Kraig Biocraft Laboratories, Inc. Gears Up to Double the Number of Genetic Insertions Performed and Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452.

May 26, 2009 (U.S. Equity News) --

Biotechnology industry alert provided by U.S. Equity News. Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date. ``We are now entering the next phase in which the team is reallocating recourses to genetic insertion,'' said CEO Kim Thompson. ``This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.''

Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (NasdaS: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure.

XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the following presentations related to its XOMA 052 anti-interleukin-1 (IL-1) beta antibody will take place at the American Diabetes Association 69th Scientific Sessions, to be held at the Morial Convention Center in New Orleans, Louisiana from June 5 to 9.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that updated interim data from the Company's ongoing Phase 2 clinical trials in frontline acute myeloid leukemia (AML) and platinum-resistant ovarian cancer and its Phase 1b/2 clinical trial in relapsed/refractory AML will be presented during the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in Orlando, Florida, which begins May 29, 2009. Following are the details on each of these data presentations.

About U.S. Equity News

U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.

U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.

Contact: U.S. Equity News Tel: (626) 961-8039 Email: info@usequitynews.com  

Newstex ID: 35283714


Source: US Equity News (May 26, 2009 - 2:33 PM EDT)

News by QuoteMedia

app.quotemedia.com/quotetools/newsStoryPopup.go

www.otcbb.com/asp/quote_module.asp

 

Fazit: Bevor man sich auf irgendwelche Insolvenz-Zocks einlässt sollte man genau lesen....

 

 

 

 

4308 Postings, 8413 Tage NukemVolumen als Vorbote?

 
  
    #19
05.06.09 10:08
Ja, hier kommt ordentlich buy-Volumen rein. Xoma spielt in einem extrem lukrativen Markt. Sollten positive Results vermeldet werden, dann ist der zukünftige Kurs noch nicht abzuschätzen. Ich bin mit einer Posi dabei. Anlageziel ca. 6 Monate.  

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuro200-Tage Linie nach oben durchgebrochen!!

 
  
    #20
2
05.06.09 11:37

gestern nachbörslich weiter gestiegen, bis 1,38$...

5662 Postings, 6062 Tage _bbb_Chart ! :-)

 
  
    #21
05.06.09 11:40

 

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroAfter Hours von gestern

 
  
    #22
2
05.06.09 12:31
After Hours
Last: $ 1.38 After Hours
High: $ 1.39
After Hours
Volume: 1,715,468 After Hours
Low: $ 1.18

Clubmitglied, 5846 Postings, 7093 Tage 10MioEuroPre-market 1,48$

 
  
    #23
2
05.06.09 12:42
Extended Hours 1.48
Last Trade  0.30 (+25.42%)

Pre-Market Change
* 200
Volume 06:36:36 AM EDT
Pre-market
1.18  
Close Price  0.33 (+38.82%)

Change* 24,646,882
Volume 06-04-2009  
Market Close
RENDERED FROM TRANSFORM: COLLECTIONS CONTENT

Clubmitglied, 5846 Postings, 7093 Tage 10MioEurodie Chart-Technik

 
  
    #24
3
07.06.09 12:24

5662 Postings, 6062 Tage _bbb_@10mio€

 
  
    #25
1
07.06.09 12:54

Das interessiert am Montag nicht nach den aktuellen News von gestern (Samstag) !!! IMO

XOMA Presents Phase 1 Diabetes Trial Data

Written by Staff and Wire Reports Saturday, 06 June 2009 14:16 http://biomedreports.com/articles/latest-news/...etes-trial-data.html

 

 

 

Seite: <
| 2 >  
   Antwort einfügen - nach oben